Functional polymorphism of the NQO2 gene is associated with methamphetamine psychosis

Addict Biol. 2005 Jun;10(2):145-8. doi: 10.1080/13556210500123423.

Abstract

Several lines of evidence suggest that genetic factors contribute to the vulnerability of drug abuse such as methamphetamine (MAP), and that dopamine-quinones produced by administration of MAP may be involved in the mechanism of MAP-related symptoms. The detoxification of quinones is catalyzed by a family of proteins designated as quinone oxidoreductases (NQOs). We analysed the polymorphisms of NQO1 and NQO2 genes to elucidate the association with genetic vulnerability to MAP abuse in Japan. The genotype and allele frequencies for the polymorphism (Pro187Ser) of the NQO1 gene did not differ between each subgroup of patients and controls. In contrast, the genotype frequency for the insertion/deletion (I/D) polymorphism in the promoter region of the NQO2 gene was a significant (p = 0.038) difference between patients with prolonged-type MAP psychosis and controls. This study suggests that the NQO2 gene polymorphism contributes to the aetiology of MAP-related psychosis in Japanese.

MeSH terms

  • Adult
  • Central Nervous System Stimulants / adverse effects*
  • DNA Primers
  • Female
  • Gene Expression
  • Genotype
  • Humans
  • Male
  • Methamphetamine / adverse effects*
  • Point Mutation / genetics
  • Polymorphism, Genetic / genetics*
  • Promoter Regions, Genetic / genetics
  • Psychoses, Substance-Induced / etiology*
  • Psychoses, Substance-Induced / genetics*
  • Quinone Reductases / genetics*
  • Restriction Mapping

Substances

  • Central Nervous System Stimulants
  • DNA Primers
  • Methamphetamine
  • NRH - quinone oxidoreductase2
  • Quinone Reductases